Exclusivity Standoff
This article was originally published in SRA
Executive Summary
Policy on `first' ANDAs for different patents on the same product
You may also be interested in...
Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about Adaptive Biotechnologies' plans to detect prior infection using T-cells obtained from blood samples.
Executives On The Move: Genmab Promotes New CMO, BiondVax And Sprint Bioscience Pick Up New CEOs
Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.
180 Life Sciences Is Looking To Repurpose Biosimilars
US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: